| Discuss | Index | Tracked By |
Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
INCY Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - 7 minutes ago from (www.businesswire.com) Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year-end 2009 financial results more ...
Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook
SGEN Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - 7 minutes ago from (www.businesswire.com) Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, more ...
Post Earnings, Biogen Idec (BIIB) Sees Unusual Options Activity
BIIB Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 09, 03:00PM from (www.bloggingstocks.com) As my colleague Karla Yeh pointed out over at ONN.tv earlier today, Biogen Idec (BIIB) saw some unusual options trading in more ...
Ride The Goldfarb 10
AES LIFE ROSE DTV DISCK Linked by Investopedia Stock Analysis ( track newsfeed | ignore newsfeed ) - February 09, 01:08PM from (stocks.investopedia.com) The Goldfarb 10 are a tempting buy for value investors. Find out why. more ...
All Eyes on Dendreon Corp.
DNDN Linked by WallStNation.com ( track newsfeed | ignore newsfeed ) - February 09, 11:43AM from (wallstnation.com) Dendreon Corporation (NASDAQ:DNDN) could have an instant $1 billion in sales if the FDA votes to approve the company's cancer more ...
Analyst Upgrades, Downgrades and Initiations: CAT, ERTS, FTNT, GME, PRSP, SAP, TWX ...
APD HES CAT ERTS STR FOSL TMRK SAP BMRN IMMR PRSP LAMR TWX PTR ENT FTNT GME HBI Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 09, 11:20AM from (www.bloggingstocks.com) Analyst Upgrades B. Riley upgraded Prosperity Bancshares (PRSP) to buy from neutral after the company acquired more ...
Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
ENZN Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 10:06AM from (www.businesswire.com) Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended more ...
OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010
OSIP Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 10:00AM from (www.businesswire.com) OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its fourth quarter and year-end 2009 financial results will more ...
Biogen Idec Reports Solid Q4 Profits and Provides Better-than-Expected Outlook
BIIB Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 09, 08:51AM from (www.streetinsider.com) more ...
Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development
CERS Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 08:30AM from (www.businesswire.com) Cerus Corporation (NASDAQ:CERS) announced a collaborative agreement with the Etablissement Français du Sang (EFS), for the more ...
Clinical Data Posts Q3 Loss of $0.63, Narrower by 2c
CLDA Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 09, 08:16AM from (www.streetinsider.com) more ...
BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
BPAX Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 08:00AM from (www.businesswire.com) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the appointment of Jeffrey W. Winkelman, Ph.D., J.D. as vice more ...
Clinical Data, Inc. Reports Third Quarter Fiscal 2010 Results
CLDA Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 07:20AM from (www.businesswire.com) Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal more ...
Biogen Reports Q4 Adj-EPS of $1.20, Beats by 15c; Guides FY10 Above the Street
BIIB Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 09, 07:16AM from (www.streetinsider.com) more ...
Biogen Idec Reports Full Year and Fourth Quarter 2009 Results
BIIB Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 07:15AM from (www.businesswire.com) Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization more ...
Cash Rich, No Debt Stocks
QLTI BIIB CHL LTON FACT Linked by Investopedia Stock Analysis ( track newsfeed | ignore newsfeed ) - February 08, 01:58PM from (stocks.investopedia.com) Anytime you can find a company with lots of cash and little or no debt, it's worth a closer look. more ...
Analyst upgrades, downgrades and initiations: CME, AZO, XOM, DNB, GENZ
XOM GENZ AZO DIS BRCM PCLN CME Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 08, 12:50PM from (www.bloggingstocks.com) Analyst upgrades: Jefferies upgraded CME Group (CME) to Buy from Hold and has a $330 target on the stock. more ...
BioMarin Pharmaceutical downgraded to "hold"
BMRN Linked by newratings ( track newsfeed | ignore newsfeed ) - February 08, 11:43AM from (www.newratings.com) NEW YORK, February 8 (newratings.com) - Analysts at Brean Murray downgrade BioMarin Pharmaceutical Inc (ticker: BMRN) from more ...
Traders Send Select Stem Cell Shares Soaring
OPXA JNJ ABT NBS GILD PSTI BCRX NVAX ATHX GERN OSIR CUR Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 08, 10:30AM from (www.tickerspy.com) The absence of notable news didn't stop speculators in the stem cell sector on Monday. Select stem cell more ...
The Unusual Suspects
AMAG AAPL MU GILD ARG APD BIDU XNPT DENN Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - February 06, 12:23PM from (247wallst.com) This past week was filled with many surprises and earnings are still coming on strong. We wanted to look at some companies more ...
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|